Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: a qualitative interview study

Nilay Hepgul; Naonori Kodate; Janet E Anderson; Max Henderson; Gopinath Ranjith; Matthew Hotopf; Carmine M Pariante

doi:10.1016/j.ijnurstu.2012.07.016

Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: a qualitative interview study

Nilay Hepgul, Naonori Kodate, Janet E Anderson, Max Henderson, Gopinath Ranjith, Matthew Hotopf, Carmine M Pariante

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) affects 170 million worldwide. Currently, around 30% of patients receiving interferon-alpha (IFN-α) treatment for HCV experience clinically significant depression. Effective and timely detection of depression is crucial to ensuring appropriate treatment and support. However, little is known about how clinical nurse specialists identify patients at risk of developing interferon-alpha-induced depression, and monitor those receiving antiviral treatment for the occurrence of depression.

Original language	English
Pages (from-to)	1480-8
Number of pages	9
Journal	International Journal of Nursing Studies
Volume	49
Issue number	12
DOIs	https://doi.org/10.1016/j.ijnurstu.2012.07.016
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijnurstu.2012.07.016

Cite this

Hepgul, N., Kodate, N., Anderson, J. E., Henderson, M., Ranjith, G., Hotopf, M., & Pariante, C. M. (2012). Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: a qualitative interview study. International Journal of Nursing Studies, 49(12), 1480-8. https://doi.org/10.1016/j.ijnurstu.2012.07.016

@article{63a0477aba354c62a479f9b0e2b0980b,

title = "Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: a qualitative interview study",

abstract = "Hepatitis C virus (HCV) affects 170 million worldwide. Currently, around 30% of patients receiving interferon-alpha (IFN-α) treatment for HCV experience clinically significant depression. Effective and timely detection of depression is crucial to ensuring appropriate treatment and support. However, little is known about how clinical nurse specialists identify patients at risk of developing interferon-alpha-induced depression, and monitor those receiving antiviral treatment for the occurrence of depression.",

author = "Nilay Hepgul and Naonori Kodate and Anderson, {Janet E} and Max Henderson and Gopinath Ranjith and Matthew Hotopf and Pariante, {Carmine M}",

year = "2012",

doi = "10.1016/j.ijnurstu.2012.07.016",

language = "English",

volume = "49",

pages = "1480--8",

journal = "International Journal of Nursing Studies",

issn = "1873-491X",

publisher = "Elsevier Limited",

number = "12",

}

Hepgul, N , Kodate, N , Anderson, JE , Henderson, M, Ranjith, G, Hotopf, M & Pariante, CM 2012, 'Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: a qualitative interview study', International Journal of Nursing Studies, vol. 49, no. 12, pp. 1480-8. https://doi.org/10.1016/j.ijnurstu.2012.07.016

TY - JOUR

T1 - Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C

T2 - a qualitative interview study

AU - Hepgul, Nilay

AU - Kodate, Naonori

AU - Anderson, Janet E

AU - Henderson, Max

AU - Ranjith, Gopinath

AU - Hotopf, Matthew

AU - Pariante, Carmine M

PY - 2012

Y1 - 2012

N2 - Hepatitis C virus (HCV) affects 170 million worldwide. Currently, around 30% of patients receiving interferon-alpha (IFN-α) treatment for HCV experience clinically significant depression. Effective and timely detection of depression is crucial to ensuring appropriate treatment and support. However, little is known about how clinical nurse specialists identify patients at risk of developing interferon-alpha-induced depression, and monitor those receiving antiviral treatment for the occurrence of depression.

AB - Hepatitis C virus (HCV) affects 170 million worldwide. Currently, around 30% of patients receiving interferon-alpha (IFN-α) treatment for HCV experience clinically significant depression. Effective and timely detection of depression is crucial to ensuring appropriate treatment and support. However, little is known about how clinical nurse specialists identify patients at risk of developing interferon-alpha-induced depression, and monitor those receiving antiviral treatment for the occurrence of depression.

U2 - 10.1016/j.ijnurstu.2012.07.016

DO - 10.1016/j.ijnurstu.2012.07.016

M3 - Article

C2 - 22889554

SN - 1873-491X

VL - 49

SP - 1480

EP - 1488

JO - International Journal of Nursing Studies

JF - International Journal of Nursing Studies

IS - 12

ER -

Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: a qualitative interview study

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this